A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show ...

Panelists discuss how key biologic and clinical distinctions—such as ischemia, leakage patterns, and modality-specific ...

It's one of the most common causes of vision loss, and one of the easiest to overlook. Glaucoma symptoms develop so gradually ...

Developed by Glaukos, the iDose TR (travoprost intraocular implant) 75 mcg is a new, FDA-approved treatment that is designed ...

Low-concentration bimatoprost 0.01%/timolol 0.1% eye gel is noninferior to the higher-concentration 0.03%/0.5% eye drops for IOP-lowering.

Sociodemographic factors, including residence in a socioeconomically distressed or rural area, can make it more likely that patients will present with advanced glaucoma.

Founded to accelerate innovation in glaucoma treatment, Glaucoma 360 is GRF’s signature event and one of the vision community’s most anticipated annual gatherings. The three-day program features a ...

Ophthalmologists discuss how advanced imaging, MIGS, and home monitoring are reshaping decision-making in complex glaucoma ...

Glaucoma remains one of the leading causes of blindness in the United States, often progressing silently until vision loss has already occurred. Known as the “silent thief of sight,” the disease ...